1
|
Jing J. The Relevance, Predictability, and Utility of Annexin A5 for Human Physiopathology. Int J Mol Sci 2024; 25:2865. [PMID: 38474114 PMCID: PMC10932194 DOI: 10.3390/ijms25052865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Revised: 02/20/2024] [Accepted: 02/26/2024] [Indexed: 03/14/2024] Open
Abstract
As an important functional protein molecule in the human body, human annexin A5 (hAnxA5) is widely found in human cells and body fluids. hAnxA5, the smallest type of annexin, performs a variety of biological functions by reversibly and specifically binding phosphatidylserine (PS) in a calcium-dependent manner and plays an important role in many human physiological and pathological processes. The free state hAnxA5 exists in the form of monomers and usually forms a polymer in a specific self-assembly manner when exerting biological activity. This review systematically discusses the current knowledge and understanding of hAnxA5 from three perspectives: physiopathological relevance, diagnostic value, and therapeutic utility. hAnxA5 affects the occurrence and development of many physiopathological processes. Moreover, hAnxA5 can be used independently or in combination as a biomarker of physiopathological phenomena for the diagnosis of certain diseases. Importantly, based on the properties of hAnxA5, many novel drug candidates have been designed and prepared for application in actual medical practice. However, there are also some gaps and shortcomings in hAnxA5 research. This in-depth study will not only expand the understanding of structural and functional relationships but also promote the application of hAnxA5 in the field of biomedicine.
Collapse
Affiliation(s)
- Jian Jing
- Beijing Key Laboratory of Biotechnology and Genetic Engineering, College of Life Sciences, Beijing Normal University, Beijing 100875, China
| |
Collapse
|
2
|
Annexin A5 ameliorates traumatic brain injury-induced neuroinflammation and neuronal ferroptosis by modulating the NF-ĸB/HMGB1 and Nrf2/HO-1 pathways. Int Immunopharmacol 2023; 114:109619. [PMID: 36700781 DOI: 10.1016/j.intimp.2022.109619] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 12/07/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022]
Abstract
Traumatic brain injury often causes poor outcomes and has few established treatments. Neuroinflammation and ferroptosis hinder therapeutic progress in this domain. Annexin A5 (A5) has anticoagulant, anti-apoptotic and anti-inflammatory bioactivities. However, its protective effects on traumatic brain injury remain unclear. Thus, we explored whether inhibiting ferroptosis and neuroinflammation using A5 could ameliorate traumatic brain injury. We injected recombinant A5 (50 µg/kg) in the tail vein of mice 30 min after fluid percussion injury. We then assessed modified neurologic severity scores, Morris water maze performance, rotarod test performance, brain water content, and blood-brain barrier permeability to document the neuroprotective effects of A5. Two days after the traumatic brain injury, we collected injured cortex tissues for western blot, Perl's staining, apoptosis staining, Nissl staining, immunofluorescence/immunohistochemistry, and enzyme-linked immunosorbent assay. We also quantified superoxide dismutase and glutathione peroxidase activity and glutathione and malondialdehyde levels. A5 improved neurological deficits, weight loss, cerebral hypoperfusion, brain edema, blood-brain barrier disruption, neuronal apoptosis, and ferroptosis. It also increased the ratio of M2/M1 phenotype microglia, reduced interleukin 1β and 6 levels, decreased peripheral immune cell infiltration, and increased interleukin 10 levels. A5 reduced neuronal iron accumulation, p53-related cell death, and oxidative stress damage. Finally, A5 downregulated HMGB1 and NF-ĸB pathways and upregulated the nuclear erythroid 2-related factor (Nrf2) and HO-1 pathways. These results suggest that A5 exerts neuroprotection in traumatic brain injury mice and ameliorates neuroinflammation, oxidative stress, and ferroptosis by regulating the NF-kB/HMGB1 pathway and the Nrf2/HO-1 antioxidant system.
Collapse
|
3
|
Méndez-Barbero N, San Sebastian-Jaraba I, Blázquez-Serra R, Martín-Ventura JL, Blanco-Colio LM. Annexins and cardiovascular diseases: Beyond membrane trafficking and repair. Front Cell Dev Biol 2022; 10:1000760. [PMID: 36313572 PMCID: PMC9614170 DOI: 10.3389/fcell.2022.1000760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 10/03/2022] [Indexed: 12/02/2022] Open
Abstract
Cardiovascular diseases (CVD) remain the leading cause of mortality worldwide. The main cause underlying CVD is associated with the pathological remodeling of the vascular wall, involving several cell types, including endothelial cells, vascular smooth muscle cells, and leukocytes. Vascular remodeling is often related with the development of atherosclerotic plaques leading to narrowing of the arteries and reduced blood flow. Atherosclerosis is known to be triggered by high blood cholesterol levels, which in the presence of a dysfunctional endothelium, results in the retention of lipoproteins in the artery wall, leading to an immune-inflammatory response. Continued hypercholesterolemia and inflammation aggravate the progression of atherosclerotic plaque over time, which is often complicated by thrombus development, leading to the possibility of CV events such as myocardial infarction or stroke. Annexins are a family of proteins with high structural homology that bind phospholipids in a calcium-dependent manner. These proteins are involved in several biological functions, from cell structural organization to growth regulation and vesicle trafficking. In vitro gain- or loss-of-function experiments have demonstrated the implication of annexins with a wide variety of cellular processes independent of calcium signaling such as immune-inflammatory response, cell proliferation, migration, differentiation, apoptosis, and membrane repair. In the last years, the use of mice deficient for different annexins has provided insight into additional functions of these proteins in vivo, and their involvement in different pathologies. This review will focus in the role of annexins in CVD, highlighting the mechanisms involved and the potential therapeutic effects of these proteins.
Collapse
Affiliation(s)
- Nerea Méndez-Barbero
- Laboratory of Vascular Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain
- CIBERCV, Madrid, Spain
| | | | - Rafael Blázquez-Serra
- Laboratory of Vascular Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain
- CIBERCV, Madrid, Spain
| | - Jose L. Martín-Ventura
- Laboratory of Vascular Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain
- CIBERCV, Madrid, Spain
- Autonoma University of Madrid, Madrid, Spain
| | - Luis M. Blanco-Colio
- Laboratory of Vascular Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain
- CIBERCV, Madrid, Spain
- *Correspondence: Luis M. Blanco-Colio,
| |
Collapse
|
4
|
Li YZ, Wang YY, Huang L, Zhao YY, Chen LH, Zhang C. Annexin A Protein Family in Atherosclerosis. Clin Chim Acta 2022; 531:406-417. [PMID: 35562096 DOI: 10.1016/j.cca.2022.05.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 05/06/2022] [Accepted: 05/06/2022] [Indexed: 12/25/2022]
Abstract
Atherosclerosis, a silent chronic vascular pathology, is the cause of the majority of cardiovascular ischaemic events. Atherosclerosis is characterized by a series of deleterious changes in cellularity, including endothelial dysfunction, transmigration of circulating inflammatory cells into the arterial wall, pro-inflammatory cytokines production, lipid accumulation in the intima, vascular local inflammatory response, atherosclerosis-related cells apoptosis and autophagy. Proteins of Annexin A (AnxA) family, the well-known Ca2+ phospholipid-binding protein, have many functions in regulating inflammation-related enzymes and cell signaling transduction, thus influencing cell adhesion, migration, differentiation, proliferation and apoptosis. There is now accumulating evidence that some members of the AnxA family, such as AnxA1, AnxA2, AnxA5 and AnxA7, play major roles in the development of atherosclerosis. This article discusses the major roles of AnxA1, AnxA2, AnxA5 and AnxA7, and the multifaceted mechanisms of the main biological process in which they are involved in atherosclerosis. Considering these evidences, it has been proposed that AnxA are drivers- and not merely participator- on the road to atherosclerosis, thus the progression of atherosclerosis may be prevented by targeting the expression or function of the AnxA family proteins.
Collapse
Affiliation(s)
- Yong-Zhen Li
- Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan province, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China
| | - Yan-Yue Wang
- Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan province, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China
| | - Liang Huang
- Research Laboratory of Translational Medicine, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China
| | - Yu-Yan Zhao
- Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan province, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China
| | - Lin-Hui Chen
- Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan province, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China
| | - Chi Zhang
- Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan province, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, People's Republic of China.
| |
Collapse
|
5
|
Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications. Apoptosis 2021; 26:534-547. [PMID: 34405304 PMCID: PMC8370750 DOI: 10.1007/s10495-021-01686-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/03/2021] [Indexed: 01/21/2023]
Abstract
Annexin A5 (anxA5) is a marker for apoptosis, but has also therapeutic potential in cardiovascular diseases, cancer, and, due to apoptotic mimicry, against dangerous viruses, which is limited by the short blood circulation. An 864-amino-acid XTEN polypeptide was fused to anxA5. XTEN864-anxA5 was expressed in Escherichia coli and purified using XTEN as tag. XTEN864-anxA5 was coupled with DTPA and indium-111. After intravenous or subcutaneous injection of 111In-XTEN864-anxA5, mouse blood samples were collected for blood half-life determination and organ samples for biodistribution using a gamma counter. XTEN864-anxA5 was labeled with 6S-IDCC to confirm binding to apoptotic cells using flow cytometry. To demonstrate targeting of atherosclerotic plaques, XTEN864-anxA5 was labeled with MeCAT(Ho) and administered intravenously to atherosclerotic ApoE−/− mice. MeCAT(Ho)-XTEN864-anxA5 was detected together with MeCAT(Tm)-MAC-2 macrophage antibodies by imaging mass cytometry (CyTOF) of aortic root sections. The ability of anxA5 to bind apoptotic cells was not affected by XTEN864. The blood half-life of XTEN864-anxA5 was 13 h in mice after IV injection, markedly longer than the 7-min half-life of anxA5. 96 h after injection, highest amounts of XTEN864-anxA5 were found in liver, spleen, and kidney. XTEN864-anxA5 was found to target the adventitia adjacent to atherosclerotic plaques. XTEN864-anxA5 is a long-circulating fusion protein that can be efficiently produced in E. coli and potentially circulates in humans for several days, making it a promising therapeutic drug.
Collapse
|
6
|
Phosphatidylserine externalized on the colonic capillaries as a novel pharmacological target for IBD therapy. Signal Transduct Target Ther 2021; 6:235. [PMID: 34131110 PMCID: PMC8206212 DOI: 10.1038/s41392-021-00626-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 04/18/2021] [Accepted: 05/01/2021] [Indexed: 02/05/2023] Open
Abstract
Inflammatory bowel disease (IBD) is a chronic and relapsing disorder for many people associated with poor health. Although there are some clinical drugs for IBD treatment, the development of effective therapeutics on IBD patients has always been necessary. Here, we show that externalized phosphatidylserine (PS) is observed on the surface of colonic capillaries. Annexin A5 (ANXA5) with high affinity for PS has a good targeting to the colon and effectively alleviates experimental colitis. In contrast, ANXA5 mutant (A5m) lacking the PS-binding ability, has no accumulation in the colon and no therapeutic effects on colitis. Mechanistic investigations indicate that ANXA5 reduces the inflammatory cell infiltration by inhibiting endothelial cell activation dependent on PS-binding ability. With the increasing of PS exposure on activated HUVECs (human umbilical vein endothelial cells), ANXA5 binding induces the internalization of TLR4 via PS-dependent endocytosis. We provide new insights on the molecular mechanism of ANXA5 for its anti-inflammatory effect. Our data suggest that PS-externalization is a potential target of ANXA5 aiming at targeted drug delivery (TDD) for IBD treatment.
Collapse
|
7
|
Méndez-Barbero N, Gutiérrez-Muñoz C, Blázquez-Serra R, Martín-Ventura JL, Blanco-Colio LM. Annexins: Involvement in cholesterol homeostasis, inflammatory response and atherosclerosis. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS 2021; 33:206-216. [PMID: 33622609 DOI: 10.1016/j.arteri.2020.12.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 12/09/2020] [Accepted: 12/16/2020] [Indexed: 11/27/2022]
Abstract
The annexin superfamily consists of 12 proteins with a highly structural homology that binds to phospholipids depending on the availability of Ca2+-dependent. Different studies of overexpression, inhibition, or using recombinant proteins have linked the main function of these proteins to their dynamic and reversible binding to membranes. Annexins are found in multiple cellular compartments, regulating different functions, such as membrane trafficking, anchoring to the cell cytoskeleton, ion channel regulation, as well as pro- or anti-inflammatory and anticoagulant activities. The use of animals deficient in any of these annexins has established their possible functions in vivo, demonstrating that annexins can participate in relevant functions independent of Ca2+ signalling. This review will focus mainly on the role of different annexins in the pathological vascular remodelling that underlies the formation of the atherosclerotic lesion, as well as in the control of cholesterol homeostasis.
Collapse
Affiliation(s)
- Nerea Méndez-Barbero
- Laboratorio de Patología Vascular, IIS-Fundación Jiménez Díaz, Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España
| | - Carmen Gutiérrez-Muñoz
- Laboratorio de Patología Vascular, IIS-Fundación Jiménez Díaz, Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España
| | | | - José Luis Martín-Ventura
- Laboratorio de Patología Vascular, IIS-Fundación Jiménez Díaz, Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España
| | - Luis Miguel Blanco-Colio
- Laboratorio de Patología Vascular, IIS-Fundación Jiménez Díaz, Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España.
| |
Collapse
|
8
|
Wu D, Huo M, Chen X, Zhang Y, Qiao Y. Mechanism of tanshinones and phenolic acids from Danshen in the treatment of coronary heart disease based on co-expression network. BMC Complement Med Ther 2020; 20:28. [PMID: 32020855 PMCID: PMC7076864 DOI: 10.1186/s12906-019-2712-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2019] [Accepted: 10/10/2019] [Indexed: 02/07/2023] Open
Abstract
Background The tanshinones and phenolic acids in Salvia miltiorrhiza (also named Danshen) have been confirmed for the treatment of coronary heart disease (CHD), but the action mechanisms remain elusive. Methods In the current study, the co-expression protein interaction network (Ce-PIN) was used to illustrate the differences between the tanshinones and phenolic acids of Danshen in the treatment of CHD. By integrating the gene expression profile data and protein-protein interactions (PPIs) data, the Ce-PINs of tanshinones and phenolic acids were constructed. Then, the Ce-PINs were analyzed by gene ontology enrichment analyzed based on the optimal algorithm. Results It turned out that Danshen is able to treat CHD by regulating the blood circulation, immune response and lipid metabolism. However, phenolic acids may regulate the blood circulation by Extracellular calcium-sensing receptor (CaSR), Endothelin-1 receptor (EDNRA), Endothelin-1 receptor (EDNRB), Kininogen-1 (KNG1), tanshinones may regulate the blood circulation by Guanylate cyclase soluble subunit alpha-1 (GUCY1A3) and Guanylate cyclase soluble subunit beta-1 (GUCY1B3). In addition, both the phenolic acids and tanshinones may regulate the immune response or inflammation by T-cell surface glycoprotein CD4 (CD4), Receptor-type tyrosine-protein phosphatase C (PTPRC). Conclusion Through the same targets of the same biological process and different targets of the same biological process, the tanshinones and phenolic acids synergistically treat coronary heart disease.
Collapse
Affiliation(s)
- Dongxue Wu
- Beijing University of Chinese Medicine, State Administration of Traditional Chinese Medicine, Research Center of TCM-Information Engineering, Beijing, 100102, China
| | - Mengqi Huo
- Beijing University of Chinese Medicine, State Administration of Traditional Chinese Medicine, Research Center of TCM-Information Engineering, Beijing, 100102, China
| | - Xi Chen
- Beijing University of Chinese Medicine, State Administration of Traditional Chinese Medicine, Research Center of TCM-Information Engineering, Beijing, 100102, China
| | - Yanling Zhang
- Beijing University of Chinese Medicine, State Administration of Traditional Chinese Medicine, Research Center of TCM-Information Engineering, Beijing, 100102, China.
| | - Yanjiang Qiao
- Beijing University of Chinese Medicine, State Administration of Traditional Chinese Medicine, Research Center of TCM-Information Engineering, Beijing, 100102, China.
| |
Collapse
|
9
|
Zhang L, Qin Z, Li R, Wang S, Wang W, Tang M, Zhang W. The role of ANXA5 in DBP-induced oxidative stress through ERK/Nrf2 pathway. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2019; 72:103236. [PMID: 31404886 DOI: 10.1016/j.etap.2019.103236] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 06/20/2019] [Accepted: 07/27/2019] [Indexed: 06/10/2023]
Abstract
Di-N-butylphthalate (DBP) have given rise to more and more attention due to its unique endocrine toxicity to male reproductive system. Our previous studies have demonstrated antioxidative Nrf2 (nuclear factor erythroid related factor 2) pathway play a vital role in DBP induced oxidative stress injury. ANXA5 (annexin A5), which is highly expressed in testicular Leydig and Sertoli cells, was found upregulated after DBP stimulation. Mouse Leydig and Sertoli cells were exposed to different concentration of DBP for 24 h to examine the ROS (Reactive oxygen species), MDA (Malondialdehyde), SOD (superoxide dismutase) level and ANXA5, Nrf2, NQO1 (NAD(P)H-quinone oxidoreductase 1), HO-1 (heme oxygenase 1) and ERK/P-ERK protein expression by DHE (Dihydroethidium) staining, ELISA (enzyme-linked immunosorbent assay) and Western blot respectively. Firstly, the oxidative stress injury induced by DBP was re-validated. Then, we confirmed the change of Nrf2 pathway and ANXA5 level after DBP exposure to testicular cells. Additionally, overexpressed ANXA5 could activate Nrf2/HO-1/NQO1 antioxidant pathway and significantly attenuate DBP-induced oxidative stress. Ultimately, we demonstrated ANXA5 could increase ERK phosphorylated level and the activated role of ANXA5 on ERK/Nrf2 pathway could be reversed by ERK inhibitor. Overall, this study illuminated that ANXA5 could defend testicle Leydig and Sertoli cells against DBP-induced oxidative stress injury through ERK/Nrf2 pathway.
Collapse
Affiliation(s)
- Lei Zhang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China
| | - Zhiqiang Qin
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China
| | - Ran Li
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China
| | - Shangqian Wang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China
| | - Wei Wang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China
| | - Min Tang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China.
| | - Wei Zhang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China.
| |
Collapse
|
10
|
de Jong RCM, Pluijmert NJ, de Vries MR, Pettersson K, Atsma DE, Jukema JW, Quax PHA. Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response. Sci Rep 2018; 8:6753. [PMID: 29712962 PMCID: PMC5928225 DOI: 10.1038/s41598-018-25143-y] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Accepted: 04/11/2018] [Indexed: 02/02/2023] Open
Abstract
Annexin A5 (AnxA5) is known to have anti-inflammatory and anti-apoptotic properties. Inflammation and apoptosis are key processes in post-ischemic cardiac remodeling. In this study, we investigated the effect of AnxA5 on left ventricular (LV) function and remodeling three weeks after myocardial ischemia-reperfusion (MI-R) injury in hypercholesterolemic ApoE*3-Leiden mice. Using a mouse model for MI-R injury, we demonstrate AnxA5 treatment resulted in a 27% reduction of contrast-enhanced MRI assessed infarct size (IS). End-diastolic and end-systolic volumes were decreased by 22% and 38%, respectively. LV ejection fraction was increased by 29% in the AnxA5 group compared to vehicle. Following AnxA5 treatment LV fibrous content after three weeks was reduced by 42%, which was accompanied by an increase in LV wall thickness of the infarcted area by 17%. Two days and three weeks after MI-R injury the number of cardiac macrophages was significantly reduced in both the infarct area and border zones following AnxA5 treatment compared to vehicle treatment. Finally, we found that AnxA5 stimulation leads to a reduction of IL-6 production in bone-marrow derived macrophages in vitro. AnxA5 treatment attenuates the post-ischemic inflammatory response and ameliorates LV remodeling which improves cardiac function three weeks after MI-R injury in hypercholesterolemic ApoE*3-Leiden mice.
Collapse
Affiliation(s)
- Rob C M de Jong
- Department of Surgery, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
| | - Niek J Pluijmert
- Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
| | - Margreet R de Vries
- Department of Surgery, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
| | | | - Douwe E Atsma
- Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
| | - J Wouter Jukema
- Department of Surgery, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.,Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
| | - Paul H A Quax
- Department of Surgery, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. .,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
| |
Collapse
|
11
|
de Vries MR, Quax PHA. Inflammation in Vein Graft Disease. Front Cardiovasc Med 2018; 5:3. [PMID: 29417051 PMCID: PMC5787541 DOI: 10.3389/fcvm.2018.00003] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Accepted: 01/08/2018] [Indexed: 12/23/2022] Open
Abstract
Bypass surgery is one of the most frequently used strategies to revascularize tissues downstream occlusive atherosclerotic lesions. For venous bypass surgery the great saphenous vein is the most commonly used vessel. Unfortunately, graft efficacy is low due to the development of vascular inflammation, intimal hyperplasia and accelerated atherosclerosis. Moreover, failure of grafts leads to significant adverse outcomes and even mortality. The last couple of decades not much has changed in the treatment of vein graft disease (VGD). However, insight is the cellular and molecular mechanisms of VGD has increased. In this review, we discuss the latest insights on VGD and the role of inflammation in this. We discuss vein graft pathophysiology including hemodynamic changes, the role of vessel wall constitutions and vascular remodeling. We show that profound systemic and local inflammatory responses, including inflammation of the perivascular fat, involve both the innate and adaptive immune system.
Collapse
Affiliation(s)
- Margreet R de Vries
- Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, Netherlands
| | - Paul H A Quax
- Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, Netherlands
| |
Collapse
|
12
|
Annexin A5 reduces early plaque formation in ApoE -/- mice. PLoS One 2017; 12:e0190229. [PMID: 29267398 PMCID: PMC5739472 DOI: 10.1371/journal.pone.0190229] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 12/11/2017] [Indexed: 01/12/2023] Open
Abstract
Annexin A5 (AnxA5) exerts anti-inflammatory, anticoagulant and anti-apoptotic effects through its binding to cell surface expressed phosphatidylserine. We previously showed that AnxA5 can stabilize advanced atherosclerotic plaques by reducing macrophage infiltration. We now investigated the effects of AnxA5 administration on the onset of atherosclerosis development. Eight-week-old ApoE-/-mice were fed a western diet while being administered AnxA5 or control (M1234) for a total of 6 weeks. AnxA5 administration reduced plaque size in the aortic root as well as the aortic arch by 36% and 55% respectively. As determined by immunohistochemistry, administration of AnxA5 further stabilized plaque by reducing macrophage content and increasing smooth muscle cell content. Furthermore, the pre-treatment of HUVEC's with AnxA5 reduced monocyte adhesion under flow-conditions. Finally, AnxA5 administration results in a trend to reduced cell death more pronounced in the aortic arch than the aortic root. In conclusion, treatment with AnxA5 before the onset of atherosclerosis reduces plaque formation in a murine model of atherosclerosis in part by reducing apoptotic rates further to its beneficial effect on macrophage infiltration and activation.
Collapse
|
13
|
Abstract
OBJECTIVE Annexin A5 (AnxA5) has been previously linked to the presence of carotid and cardiac target organ damage (TOD) in the context of heart failure and rheumatologic patients. However, information is scant in the context of hypertension. Aim of our study was to evaluate AnxA5 in treated hypertension patients compared with normotensive controls and to determine whether it is associated with vascular and heart TOD evaluated as arterial stiffness, carotid plaque and left ventricular hypertrophy. METHODS We enrolled 123 consecutive treated hypertension and 124 normotensive controls. TOD was evaluated as pulse wave velocity (PWV, complior), left ventricular hypertrophy (echocardiography) and intima-media thickness and carotid plaque presence (ecographic methods). AnxA5 levels was dosed and compared in patients with and without hypertension and with and without TOD. RESULTS With similar age hypertension patients showed higher SBP, DBP and AnxA5 levels (13.9 ± 11.1 vs 10.1 ± 8.4 ng/ml, P < 0.001) compared with controls. Regarding TOD hypertension showed higher PWV (8.5 ± 1.8 vs 7.6 ± 1.5 m/s, P < 0.001) and LVMI (121.7 ± 29.3 vs 113.5 ± 21.1 g/m, P < 0.05), whereas carotid intima-media thickness was superimposable. AnxA5 correlates with PWV (r = 0.13, P < 0.05) and DBP (r = 0.15, P < 0.01), whereas it has never been found as a significant independent predictor of TOD in linear regression analysis. CONCLUSION Our data have shown that AnxA5 levels are increased in treated hypertension patients. In this condition, it is probably released in the plasma as a defensive mechanism through its anti-inflammatory and anticoagulants effects. We found a significant association with arterial stiffness, but AnxA5 was not found to be a significant predictor of TOD.
Collapse
|
14
|
Burgmaier M, Reith S, Schurgers L, Kahles F, Marx N, Reutelingsperger C. Circulating annexin A5 levels are associated with carotid intima-media thickness but not coronary plaque composition. Diab Vasc Dis Res 2017; 14:415-422. [PMID: 28592134 DOI: 10.1177/1479164117710392] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
BACKGROUND Annexin A5 (anxA5) is involved in processes which are crucial in atherogenesis. However, anxA5's relationship with atherosclerotic lesion extension and plaque composition in high-risk patients with type 2 diabetes remains unclear. Thus, we characterized the association between circulating anxA5 levels with atherosclerotic burden and coronary plaque composition in diabetes mellitus patients. METHODS Intima-media thickness was determined in 96 diabetes mellitus patients with stable coronary artery disease. Furthermore, intracoronary optical coherence tomography was performed in 106 lesions to determine plaque composition. RESULTS AnxA5 plasma levels of patients with intima-media thickening were higher (3.49 ± 2.19 ng/mL) compared to patients with normal intima-media thickness (2.24 ± 1.67 ng/mL, p = 0.002). Furthermore, anxA5 was associated with intima-media thickening on univariable [odds ratio = 1.445 (1.106-1.889), p = 0.007] and multivariable [odds ratio = 1.643 (1.166-2.314), p = 0.005] logistic regression analysis when adjusted for multiple cardiovascular risk factors and biomarkers. Furthermore, receiver operating characteristic analysis demonstrated that anxA5 predicted intima-media thickening with low-moderate diagnostic efficiency [area under the curve = 0.700 (0.592-0.808)]. In contrast, there was no association between anxA5 levels and coronary plaque composition as assessed by optical coherence tomography including the presence of lipid, calcified, fibrous plaque or the minimal thickness of the fibrous cap overlying the necrotic lipid core ( p = ns). CONCLUSION Circulating anxA5 levels are associated with carotid intima-media thickness but not coronary plaque composition in high-risk patients with diabetes mellitus.
Collapse
Affiliation(s)
- Mathias Burgmaier
- 1 Department of Cardiology, Medical Clinic I, University Hospital of the RWTH Aachen, Aachen, Germany
| | - Sebastian Reith
- 1 Department of Cardiology, Medical Clinic I, University Hospital of the RWTH Aachen, Aachen, Germany
| | - Leon Schurgers
- 2 Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| | - Florian Kahles
- 1 Department of Cardiology, Medical Clinic I, University Hospital of the RWTH Aachen, Aachen, Germany
| | - Nikolaus Marx
- 1 Department of Cardiology, Medical Clinic I, University Hospital of the RWTH Aachen, Aachen, Germany
| | - Chris Reutelingsperger
- 2 Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
15
|
Candidate Gene Analysis of Mortality in Dialysis Patients. PLoS One 2015; 10:e0143079. [PMID: 26587841 PMCID: PMC4654483 DOI: 10.1371/journal.pone.0143079] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2015] [Accepted: 10/31/2015] [Indexed: 12/19/2022] Open
Abstract
Background Dialysis patients have high cardiovascular mortality risk. This study aimed to investigate the association between SNPs of genes involved in vascular processes and mortality in dialysis patients. Methods Forty two SNPs in 25 genes involved in endothelial function, vascular remodeling, cell proliferation, inflammation, coagulation and calcium/phosphate metabolism were genotyped in 1330 incident dialysis patients. The effect of SNPs on 5-years cardiovascular and non-cardiovascular mortality was investigated. Results The mortality rate was 114/1000 person-years and 49.4% of total mortality was cardiovascular. After correction for multiple testing, VEGF rs699947 was associated with all-cause mortality (HR1.48, 95% CI 1.14–1.92). The other SNPs were not associated with mortality. Conclusions This study provides further evidence that a SNP in the VEGF gene may contribute to the comorbid conditions of dialysis patients. Future studies should unravel the underlying mechanisms responsible for the increase in mortality in these patients.
Collapse
|
16
|
Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM, Grommes J, Hinkel R, Kupatt C, Weber C, Döring Y, Zarbock A, Soehnlein O. Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ Res 2014; 116:827-35. [PMID: 25520364 DOI: 10.1161/circresaha.116.305825] [Citation(s) in RCA: 118] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
RATIONALE Chemokine-controlled arterial leukocyte recruitment is a crucial process in atherosclerosis. Formyl peptide receptor 2 (FPR2) is a chemoattractant receptor that recognizes proinflammatory and proresolving ligands. The contribution of FPR2 and its proresolving ligand annexin A1 to atherosclerotic lesion formation is largely undefined. OBJECTIVE Because of the ambivalence of FPR2 ligands, we here investigate the role of FPR2 and its resolving ligand annexin A1 in atherogenesis. METHODS AND RESULTS Deletion of FPR2 or its ligand annexin A1 enhances atherosclerotic lesion formation, arterial myeloid cell adhesion, and recruitment. Mechanistically, we identify annexin A1 as an endogenous inhibitor of integrin activation evoked by the chemokines CCL5, CCL2, and CXCL1. Specifically, the annexin A1 fragment Ac2-26 counteracts conformational activation and clustering of integrins on myeloid cells evoked by CCL5, CCL2, and CXCL1 through inhibiting activation of the small GTPase Rap1. In vivo administration of Ac2-26 largely diminishes arterial recruitment of myeloid cells in a FPR2-dependent fashion. This effect is also observed in the presence of selective antagonists to CCR5, CCR2, or CXCR2, whereas Ac2-26 was without effect when all 3 chemokine receptors were antagonized simultaneously. Finally, repeated treatment with Ac2-26 reduces atherosclerotic lesion sizes and lesional macrophage accumulation. CONCLUSIONS Instructing the annexin A1-FPR2 axis harbors a novel approach to target arterial leukocyte recruitment. With the ability of Ac2-26 to counteract integrin activation exerted by various chemokines, delivery of Ac2-26 may be superior in inhibition of arterial leukocyte recruitment when compared with blocking individual chemokine receptors.
Collapse
Affiliation(s)
- Maik Drechsler
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Renske de Jong
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Jan Rossaint
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Joana R Viola
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Giovanna Leoni
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Ji Ming Wang
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Jochen Grommes
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Rabea Hinkel
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Christian Kupatt
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Christian Weber
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Yvonne Döring
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Alexander Zarbock
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.)
| | - Oliver Soehnlein
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen-Maastricht, University Hospital RWTH Aachen, Aachen, Germany (J.G.); Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich, Munich, Germany (R.H., C.K.); and DZHK, Partner Site Munich Heart Alliance, Munich, Germany (R.H., C.K., C.W., O.S.).
| |
Collapse
|
17
|
Hiddink L, Dallinga-Thie GM, Hovingh GK, de Visser MCH, Peer PGM, Stalenhoef AFH, van Heerde WL. Annexin A5 haplotypes in familial hypercholesterolemia: lack of association with carotid intima-media thickness and cardiovascular disease risk. Atherosclerosis 2014; 238:195-200. [PMID: 25525746 DOI: 10.1016/j.atherosclerosis.2014.11.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2014] [Revised: 11/14/2014] [Accepted: 11/28/2014] [Indexed: 01/19/2023]
Abstract
OBJECTIVE Annexin A5 (ANXA5) has been suggested to possess antiatherogenic properties. We investigated whether ANXA5 genetic variations and plasma ANXA5 levels were associated with carotid atherosclerosis and contributed to cardiovascular disease (CVD) risk in patients with familial hypercholesterolemia (FH). METHODS We sequenced the promoter region and exon 2 of ANXA5 in 284 FH patients from the ASAP (Atorvastatin versus Simvastatin on Atherosclerosis Progression) trial. Common haplotypes (H) were constructed based on seven single nucleotide polymorphisms (SNPs). We studied whether plasma ANXA5 levels or ANXA5 haplotypes were associated with the extent of atherosclerosis (evaluated by carotid intima-media thickness (IMT). The association between ANXA5 haplotypes and the risk for CVD events was investigated in 1730 FH patients from the GIRaFH (Genetic Identification of Risk factors in Familial Hypercholesterolemia) study. RESULTS In ASAP, individuals carrying the ANXA5 haplotype H2 exhibited lower plasma ANXA5 levels, whereas H4 carriers had increased levels of circulating ANXA5 compared to non-carriers. Plasma ANXA5 levels were not associated with carotid IMT. None of the four ANXA5 haplotypes correlated with the age-related IMT progression (ASAP study) or contributed to CVD risk (GIRaFH cohort). CONCLUSIONS Both ANXA5 haplotypes and plasma ANXA5 levels were not associated with carotid IMT progression or CVD risk in FH patients.
Collapse
Affiliation(s)
- Larissa Hiddink
- Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands
| | - Geesje M Dallinga-Thie
- Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
| | - G Kees Hovingh
- Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
| | - Marieke C H de Visser
- Department for Health Evidence, Radboud University Medical Center, Geert Grooteplein 21, 6525 EZ Nijmegen, The Netherlands
| | - Petronella G M Peer
- Department for Health Evidence, Radboud University Medical Center, Geert Grooteplein 21, 6525 EZ Nijmegen, The Netherlands
| | - Anton F H Stalenhoef
- Department of General Internal Medicine, Radboud University Medical Center, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands
| | - Waander L van Heerde
- Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands.
| |
Collapse
|
18
|
Burgmaier M, Schutters K, Willems B, van der Vorst EPC, Kusters D, Chatrou M, Norling L, Biessen EAL, Cleutjens J, Perretti M, Schurgers LJ, Reutelingsperger CPM. AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice. J Cell Mol Med 2014; 18:2117-24. [PMID: 25214012 PMCID: PMC4244025 DOI: 10.1111/jcmm.12374] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Accepted: 06/13/2014] [Indexed: 12/28/2022] Open
Abstract
Annexin A5 (AnxA5) exerts anti-inflammatory, anticoagulant and anti-apoptotic effects through binding cell surface expressed phosphatidylserine. The actions of AnxA5 on atherosclerosis are incompletely understood. We investigated effects of exogenous AnxA5 on plaque morphology and phenotype of advanced atherosclerotic lesions in apoE−/− mice. Advanced atherosclerotic lesions were induced in 12 weeks old Western type diet fed apoE−/− mice using a collar placement around the carotid artery. After 5 weeks mice were injected either with AnxA5 (n = 8) or vehicle for another 4 weeks. AnxA5 reduced plaque macrophage content both in the intima (59% reduction, P < 0.05) and media (73% reduction, P < 0.01) of advanced atherosclerotic lesions of the carotid artery. These findings corroborated with advanced lesions of the aortic arch, where a 67% reduction in plaque macrophage content was observed with AnxA5 compared to controls (P < 0.01). AnxA5 did not change lesion extension, plaque apoptosis, collagen content, smooth muscle cell content or acellular plaque composition after 4 weeks of treatment as determined by immunohistochemistry in advanced carotid lesions. In vitro, AnxA5 exhibited anti-inflammatory effects in macrophages and a flow chamber based assay demonstrated that AnxA5 significantly inhibited capture, rolling, adhesion as well as transmigration of peripheral blood mononuclear cells on a TNF-α-activated endothelial cell layer. In conclusion, short-term treatment with AnxA5 reduces plaque inflammation of advanced lesions in apoE−/− mice likely through interfering with recruitment and activation of monocytes to the inflamed lesion site. Suppressing chronic inflammation by targeting exposed phosphatidylserine may become a viable strategy to treat patients suffering from advanced atherosclerosis.
Collapse
Affiliation(s)
- Mathias Burgmaier
- Department of Internal Medicine I, University Hospital of the RWTH Aachen, Aachen, Germany; Department of Biochemistry, Maastricht University, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Wan M, Hua X, Su J, Thiagarajan D, Frostegård AG, Haeggström JZ, Frostegård J. Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5. Atherosclerosis 2014; 235:592-8. [PMID: 24956533 DOI: 10.1016/j.atherosclerosis.2014.05.913] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Revised: 04/25/2014] [Accepted: 05/01/2014] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Cardiolipin (CL) is a phospholipid with an unusual dimeric structure containing four double-bonds and is easily oxidized. CL is present in mitochondria. Here we explored potential pro-inflammatory properties implicated in cardiovascular disease (CVD): activation of endothelial cells, 5-lipoxygenase (5-LOX) and leukotriene B4 (LTB4), by oxidized CL (oxCL) and inhibitory effects of Annexin A5, an antithrombotic and antiinflammatory plasma protein. METHODS In monocytes/macrophages and neutrophils, calcium mobilization was monitored spectrophotometrically with Fura-2 and synthesis of LTB4 was analyzed by EIA. Expression of adhesion molecules on endothelial cells was studied by FACScan. Binding of Annexin A5 were analyzed by ELISA. The mRNA expression of 5-LOX and cyclooxygenase-2 was assessed by Real-Time PCR. RESULTS We demonstrate that oxCL but not its non-oxidized counterpart CL induces biosynthesis of LTB4 and increases intracellular concentrations of calcium in monocytes/macrophages and neutrophils. oxCL rather than CL selectively elevates gene expression of 5-LOX but not COX-2 in human macrophages. Furthermore, oxCL but not CL raises levels of adhesion molecules ICAM-1 and VCAM-1 in endothelial cells. Annexin A5 can bind oxCL to abolish all these oxCL-induced effects. CONCLUSIONS oxCL may promote inflammation and related diseases especially in conditions involving unresolved apoptosis and necrosis, such as atherosclerosis, where free oxCL is likely to be released from liberated mitochondria. Increased intracellular calcium could activate 5-LOX to produce Leukotriene B4 (LTB4). Annexin A5 inhibits the pro-inflammatory effects of oxCL and its potential therapeutic use when oxCL is implicated in inflammation could be of interest.
Collapse
Affiliation(s)
- Min Wan
- Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - Xiang Hua
- IMM, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Divisions of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Insitutet, Stockholm, Sweden.
| | - Jun Su
- IMM, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Divya Thiagarajan
- IMM, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Anna G Frostegård
- IMM, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Jesper Z Haeggström
- Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - Johan Frostegård
- IMM, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Divisions of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Insitutet, Stockholm, Sweden; Acute Internal Medicine, Karolinska University Hospital, Huddinge, Sweden
| |
Collapse
|
20
|
Seok H, Park HJ, Lee BW, Kim JW, Jung M, Lee SR, Park KH, Park YG, Baik HH, Chung JH. Association of annexin A5 polymorphisms with obesity. Biomed Rep 2013; 1:654-658. [PMID: 24649004 DOI: 10.3892/br.2013.118] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2013] [Accepted: 05/10/2013] [Indexed: 01/21/2023] Open
Abstract
Annexin A5 (ANXA5), which is known as a protein with anticoagulative function, may play a role in triglyceride biosynthesis. Triglycerides are involved in lipid and energy metabolism, which are important in the elucidation of obesity. To investigate the association between single-nucleotide polymorphisms (SNPs) of ANXA5 and obesity in a Korean population, 372 participants (213 overweight/obese individuals and 159 control subjects) were enrolled from the Kyung Hee University Medical Center and Keimyung University Dongsan Medical Center. The genotypes of five SNPs (rs12510548, rs4240260, rs3756281, rs13136094 and rs6534313) were evaluated in ANXA5 using the multiple logistic regression analysis with the codominant 1, codominant 2, dominant, recessive and log-additive models. The genotype and allele frequencies of the five investigated SNPs exhibited significant differences between the control and the overweight/obese groups: rs12510548 (P=0.004 in the codominant 2 model, P=0.0019 in the recessive model, P=0.027 in the log-additive model and P=0.026 in allele frequencies); rs4240260 (P=0.002 and Fisher's exact P=0.0006 in the codominant 2 model, P=0.0007 and Fisher's exact P=0.0007 in the recessive model, P=0.020 and Fisher's exact P=0.0019 in the log-additive model and P=0.020 in allele frequencies); rs3756281 (P=0.016 in the codominant 2 model and P=0.0094 in the recessive model); rs13136094 (P=0.0030 and Fisher's exact P=0.0011 in the codominant 2 model, P=0.0012 and Fisher's exact P=0.0013 in the recessive model, P=0.034 and Fisher's exact P=0.0035 in the log-additive model and P=0.024 in allele frequencies); and rs6534313 (P=0.0010 and Fisher's exact P=0.0003 in the codominant 2 model, P=0.0003 and Fisher's exact P=0.0003 in the recessive model, P=0.0075 and Fisher's exact P=0.0010 in the log-additive model and P=0.005 in allele frequencies). Two haplotypes were weakly associated with obesity (GGATG, P=0.037 and CAGCC, P=0.020). Results of the present study suggested that ANXA5 may be associated with the development of obesity in a Korean population.
Collapse
Affiliation(s)
- Hosik Seok
- Departments of Pharmacology and Kohwang Medical Research Institute, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Hae Jeong Park
- Departments of Pharmacology and Kohwang Medical Research Institute, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Byoung Wook Lee
- Biochemistry and Molecular Biology, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Jong Woo Kim
- Neuropsychiatry, School of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Min Jung
- Department of Orthodontics, School of Dentistry, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Seo Ra Lee
- Department of Orthodontics, School of Dentistry, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Ki Ho Park
- Department of Orthodontics, School of Dentistry, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Young Guk Park
- Department of Orthodontics, School of Dentistry, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Hyung Hwan Baik
- Biochemistry and Molecular Biology, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Joo-Ho Chung
- Departments of Pharmacology and Kohwang Medical Research Institute, Kyung Hee University, Seoul 130-701, Republic of Korea
| |
Collapse
|